Fresh insights could lead to new treatments for liver disease
Press release issued: 9 October 2019
The fight against liver disease could be helped by the discovery of cells that cause liver scarring. Scientists have identified new sub-types of cells that, when they interact, accelerate the scarring process in diseased livers. Experts hope that by understanding more how these cells behave, new treatments can be developed more quickly for liver diseases.
One in five people in the UK are at risk of developing liver disease. It is predicted to become the most common cause of premature death in the UK. It can occur as a result of a number of conditions such as obesity, alcohol excess, viral infections, autoimmune diseases or genetic disorders. Long-term damage leads to the formation of scar tissue within the liver, eventually causing liver failure. There are currently no treatments available to prevent or reverse this.
Scientists from the University of Edinburgh, in collaboration with the universities of Birmingham, Bristol, Cambridge, Charité University Medical Center, National Institute for Health Research (NIHR) Bristol Biomedical Research Centre (BRC) and NIHR Birmingham BRC, used a new technology called single cell RNA sequencing to study liver scarring in high definition.
They discovered sub-types of three key cells: white blood cells called macrophages, endothelial cells – which line blood vessels – and scar-forming cells known as myofibroblasts.
The study, published in Nature, was funded by the Wellcome Trust, Medical Research Council, Guts UK, Children's Liver Disease Foundation, AbbVie pharmaceuticals, Tenovus Scotland, British Heart Foundation, and NIHR.
Dr Prakash Ramachandran, an MRC clinician scientist at the University of Edinburgh's Centre for Inflammation Research and Consultant Liver Specialist at the Royal Infirmary of Edinburgh said: "Identifying new treatments for liver scarring is critical to tackling the epidemic of liver disease that we are currently facing. For the first time, we now have an in-depth understanding of how cells behave and talk to each other in diseased livers and, importantly, how we might block their activity as a treatment for liver scarring."
Professor Neil Henderson, a Wellcome Trust Senior Research Fellow at the Centre for Inflammation Research and Consultant Liver Specialist at the Royal Infirmary of Edinburgh, explained: "Using this new technology has allowed us to study human liver scarring in high definition for the first time. We hope that this new cutting-edge approach will rapidly accelerate the discovery of much-needed new treatments for patients with liver disease."
Dr Sarah Teichmann, from the Wellcome Sanger Institute, University of Cambridge and co-chair of the Human Cell Atlas Organising Committee, said: "The discovery of three new sub-types of cell involved in human liver scarring is another important moment in the fight against liver disease and for the Human Cell Atlas initiative. The data is now publicly available for other researchers to use and will be a great resource as we attempt to tackle this epidemic."
Professor John Iredale, Pro Vice-Chancellor for Health at the University of Bristol, added: "This work is critical in our effort to identify new targets to treat the increasing burden of liver disease. It is hoped and anticipated that this important data in human disease will catalyse and fast -track research in this important model of scarring disease."
'Resolving the fibrotic niche of human liver cirrhosis at single-cell level' by N. C. Henderson, P. Ramachandran et al in Nature
About the National Institute for Health Research (NIHR)
The National Institute for Health Research (NIHR) is the nation's largest funder of health and care research. The NIHR:
- Funds, supports and delivers high quality research that benefits the NHS, public health and social care
- Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
- Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
- Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
- Partners with other public funders, charities and industry to maximise the value of research to patients and the economy
The NIHR was established in 2006 to improve the health and wealth of the nation through research, and is funded by the Department of Health and Social Care. In addition to its national role, the NIHR supports applied health research for the direct and primary benefit of people in low- and middle-income countries, using UK aid from the UK government.
About NIHR Bristol BRC
The research centre, awarded to University Hospitals Bristol NHS Foundation Trust (UH Bristol) and the University of Bristol by the NIHR, conducts cutting-edge research to develop new, ground-breaking treatments, diagnostics, prevention and care for patients in a wide range of diseases.
Led by John Iredale (Bristol Pro Vice Chancellor for Health) and Jonathan Sterne, NIHR Bristol BRC has research themes on Cardiovascular Research (led by Gianni Angelini) Nutrition, Diet and Lifestyle (led by Andy Ness), Mental Health (led by David Gunnell), Perinatal and Reproductive Health (led by Debbie Lawlor) and Surgical Innovation (led by Jane Blazeby). The research themes are underpinned by cross-cutting themes in Translational Population Science (led by George Davey Smith) and Biostatistics, Evidence Synthesis and Informatics (led by Jonathan Sterne).
A strand of population health science runs through all themes of the BRC, with a focus on translating scientific discoveries that have arisen from population science into better care for NHS patients.